Evidence map›Paper›PMID 31750247›Full record

ReviewFrontiers in oncology2019

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma.

Yongting Lai, Bing Feng, Mubalake Abudoureyimu, Yingru Zhi, Hao Zhou, Ting Wang, Xiaoyuan Chu, Ping Chen, Rui Wang

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Yongting LaiDepartment of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China.
Bing FengDepartment of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.
Mubalake AbudoureyimuDepartment of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.
Yingru ZhiDepartment of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.
Hao ZhouDepartment of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China.
Ting WangDepartment of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.
Xiaoyuan ChuDepartment of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China.
Ping ChenDepartment of Oncology, First People's Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng, China.
Rui WangDepartment of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China.
Nanjing University · CNSouthern Medical University · CNAffiliated Hospital of Nantong University · CNNanjing General Hospital of Nanjing Military Command · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), and long non-coding (lncRNAs), have recently been demonstrated playing critical roles in a variety of cancers including HCC, while the mechanisms of ncRNAs in HCC sorafenib resistance have not been extensively characterized yet. Herein, we summarize the mechanisms of recently reported ncRNAs involved in sorafenib resistance and discuss the potential strategies for their application in the battle against HCC.

Indexed as

hepatocellular carcinoma (HCC)long non-coding RNAs (lncRNAs)microRNAs (miRNAs)non-coding RNAs (ncRNAs)sorafenib resistance

Identifiers

PMID31750247
PMCPMC6848262
OpenAlexW2981485898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.